400 related articles for article (PubMed ID: 17632222)
1. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Zhai JG; Guo XF; Guo WB
J Clin Psychopharmacol; 2007 Aug; 27(4):374-9. PubMed ID: 17632222
[TBL] [Abstract][Full Text] [Related]
2. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.
Wu RR; Zhao JP; Liu ZN; Zhai JG; Guo XF; Guo WB; Tang JS
Psychopharmacology (Berl); 2006 Jul; 186(4):572-8. PubMed ID: 16601995
[TBL] [Abstract][Full Text] [Related]
3. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
Murashita M; Inoue T; Kusumi I; Nakagawa S; Itoh K; Tanaka T; Izumi T; Hosoda H; Kangawa K; Koyama T
Psychiatry Clin Neurosci; 2007 Feb; 61(1):54-8. PubMed ID: 17239039
[TBL] [Abstract][Full Text] [Related]
4. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity.
Wu MK; Huang CY; Liou YJ; Wang CK; Lee SD
Int J Obes (Lond); 2008 Mar; 32(3):436-42. PubMed ID: 17955031
[TBL] [Abstract][Full Text] [Related]
5. Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study.
Rettenbacher MA; Hummer M; Hofer A; Baumgartner S; Ebenbichler C; Edlinger M; Kemmler G; Lechleitner M; Wolfgang Fleischhacker W
J Psychopharmacol; 2007 Jun; 21(4):400-4. PubMed ID: 17050656
[TBL] [Abstract][Full Text] [Related]
6. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
[TBL] [Abstract][Full Text] [Related]
7. Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: a prospective study.
Chen Q; Cai ZJ; Mao PX; Zhai YM; Mitchell PB; Tang YL
J Psychiatr Res; 2008 Dec; 43(2):124-8. PubMed ID: 18423490
[TBL] [Abstract][Full Text] [Related]
8. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.
Tschoner A; Engl J; Rettenbacher M; Edlinger M; Kaser S; Tatarczyk T; Effenberger M; Patsch JR; Fleischhacker WW; Ebenbichler CF
Pharmacopsychiatry; 2009 Jan; 42(1):29-34. PubMed ID: 19153944
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
[TBL] [Abstract][Full Text] [Related]
10. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone.
Henderson DC; Sharma B; Fan X; Copeland PM; Borba CP; Freudenreich O; Cather C; Evins AE; Goff DC
Ann Clin Psychiatry; 2010 Feb; 22(1):33-42. PubMed ID: 20196981
[TBL] [Abstract][Full Text] [Related]
11. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
12. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
13. Effects of subchronic clozapine administration on serum glucose, cholesterol and triglyceride levels, and body weight in male BALB/c mice.
Cheng CY; Hong CJ; Tsai SJ
Life Sci; 2005 Mar; 76(19):2269-73. PubMed ID: 15733941
[TBL] [Abstract][Full Text] [Related]
14. Effects of second generation antipsychotics on leptin and ghrelin.
Esen-Danaci A; Sarandöl A; Taneli F; Yurtsever F; Ozlen N
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1434-8. PubMed ID: 18579280
[TBL] [Abstract][Full Text] [Related]
15. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.
Palik E; Birkás KD; Faludi G; Karádi I; Cseh K
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S60-4. PubMed ID: 15955378
[TBL] [Abstract][Full Text] [Related]
16. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
17. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
18. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.
Dursun SM; Szemis A; Andrews H; Reveley MA
J Psychiatry Neurosci; 1999 Nov; 24(5):453-5. PubMed ID: 10586536
[TBL] [Abstract][Full Text] [Related]
19. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Krakowski M; Czobor P; Citrome L
Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
[TBL] [Abstract][Full Text] [Related]
20. The effect of clozapine on glucose metabolism.
Yazici KM; Erbas T; Yazici AH
Exp Clin Endocrinol Diabetes; 1998; 106(6):475-7. PubMed ID: 10079027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
